Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-grade myofibrosarcoma of the maxillary sinus: Two case reports.
Mydlak A, Ścibik Ł, Durzynska M, Zwoliński J, Buchajska K, Lenartowicz O, Kucharz J. Mydlak A, et al. World J Clin Oncol. 2024 Apr 24;15(4):566-575. doi: 10.5306/wjco.v15.i4.566. World J Clin Oncol. 2024. PMID: 38689628 Free PMC article.
Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
Domański P, Piętak M, Staneta S, Fortuniak W, Kruczyk B, Kobiernik A, Bakuła P, Mydlak A, Demkow T, Sikora-Kupis B, Dumnicka P, Kucharz J. Domański P, et al. Among authors: mydlak a. Medicina (Kaunas). 2024 Feb 26;60(3):398. doi: 10.3390/medicina60030398. Medicina (Kaunas). 2024. PMID: 38541124 Free PMC article. Review.
Adverse Events of Cabozantinib as a Potential Prognostic Factor in Metastatic Renal Cell Carcinoma Patients: Real-World Experience in a Single-Center Retrospective Study.
Domański P, Piętak M, Kruczyk B, Jarosińska J, Mydlak A, Demkow T, Darewicz M, Sikora-Kupis B, Dumnicka P, Kamzol W, Kucharz J. Domański P, et al. Among authors: mydlak a. Biomedicines. 2024 Feb 9;12(2):413. doi: 10.3390/biomedicines12020413. Biomedicines. 2024. PMID: 38398014 Free PMC article.
Activity of cabozantinib in further line treatment of metastatic clear cell renal cell carcinoma. Real-world experience in a single-center retrospective study.
Domański P, Jarosińska J, Kruczyk B, Piętak M, Mydlak A, Demkow T, Kuncman Ł, Darewicz M, Sikora-Kupis B, Dumnicka P, Kucharz J. Domański P, et al. Among authors: mydlak a. Contemp Oncol (Pozn). 2023;27(3):190-197. doi: 10.5114/wo.2023.133545. Epub 2023 Dec 7. Contemp Oncol (Pozn). 2023. PMID: 38239858 Free PMC article.
Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study.
Domański P, Jarosińska J, Kruczyk B, Piętak M, Mydlak A, Demkow T, Kuncman Ł, Darewicz M, Sikora-Kupis B, Michalski W, Kucharz J. Domański P, et al. Among authors: mydlak a. Contemp Oncol (Pozn). 2023;27(4):242-248. doi: 10.5114/wo.2023.134786. Epub 2024 Jan 30. Contemp Oncol (Pozn). 2023. PMID: 38405212 Free PMC article.
First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure.
Sikora-Kupis B, Domański P, Fortuniak W, Kruczyk B, Staneta S, Piętak M, Mydlak A, Demkow T, Dumnicka P, Kucharz J. Sikora-Kupis B, et al. Among authors: mydlak a. Contemp Oncol (Pozn). 2023;27(4):224-229. doi: 10.5114/wo.2023.134751. Epub 2024 Feb 10. Contemp Oncol (Pozn). 2023. PMID: 38405211 Free PMC article.